Table 8.
Screening and Treatment Practice Patterns for CVD Disease Risk Factors in Pediatric CureGN Subjects
| n/N (%) | Overall (n=761) | MCD (n=283) | FSGS (n=177) | MN (n=36) | IgAN/IgAV (n=265) | P value |
|---|---|---|---|---|---|---|
| Patients with any hypertensiona, whole cohortb | 268/761 (35) | 108/283 (38) | 70/177 (40) | 19/36 (53) | 71/265 (27) | 0.001 |
| Number on any antihypertensive medication | 197/268 (74) | 74/108 (69) | 59/70 (84) | 14/19 (74) | 50/71 (70) | 0.12 |
| Number on RAAS blocker | 181/268 (68) | 68/108 (63) | 54/70 (77) | 14/19 (74) | 45/71 (63) | 0.18 |
| Patients on RAAS blocker, whole cohortb | 444/761 (58) | 120/283 (42) | 130/177 (73) | 24/36 (67) | 170/265 (64) | <0.001 |
| Among those with UPCR >2 | 98/168 (58) | 30/62 (48) | 35/51 (69) | 9/15 (60) | 24/40 (60) | 0.19 |
| Patients prescribed lipid‐ lowering medication, whole cohortb | 78/761 (10) | 9/283 (3) | 17/177 (10) | 6/36 (17) | 46/265 (17) | <0.001 |
| Among patients with lipid profile measured | 35/372 (9) | 5/172 (3) | 13/94 (14) | 6/22 (27) | 11/84 (13) | <0.001 |
| Among patients with TC >200 mg/dLc | 19/224 (9) | 4/120 (3) | 8/54 (15) | 6/18 (33) | 1/32 (3) | <0.001 |
| Among patients with dyslipidemia of any type | 25/265 (9) | 4/132 (3) | 9/67 (13) | 6/20 (30) | 6/46 (13) | <0.001 |
CureGN indicates Cure Glomerulonephropathy Network; CVD, cardiovascular disease; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN, membranous nephropathy; RAAS blocker, renin‐angiotensin‐aldosterone system blocker; TC, total cholesterol; UPCR, urine protein‐to‐creatinine ratio.
a
Self‐reported history or enrollment systolic and/or diastolic blood pressure >95th percentile.
b
<1% missing.
c
Total cholesterol: MCD missing 41%, FSGS missing 48%, MN missing 39%, IgAN missing 70%.